Tag: Keytruda

In 2024, the global orphan drug market reached an estimated revenue of nearly $190 billion, illustrating the significant financial impact of these medications. This success raises the question: **What is the highest grossing orphan drug?** The answer is more complex than it appears, as many top sellers have expanded indications far beyond their initial orphan status.

KEYTRUDA (pembrolizumab) is an immunotherapy medicine that works with the immune system to treat certain cancers [1.3.6]. Understanding **what to expect after a KEYTRUDA infusion** is key to managing your health, from common side effects like fatigue to more serious immune-related reactions [1.2.1].

Since its first FDA approval in 2014, KEYTRUDA (pembrolizumab) has become a treatment for over 20 types of cancer [1.4.3]. A common question for patients is, **how long does KEYTRUDA stay in your system after an infusion?**

Based on 2024 sales figures, Merck's Keytruda, a powerful immuno-oncology drug, was what's the highest selling drug globally, solidifying its position as a monumental cancer treatment. However, the dynamic pharmaceutical market continues to shift, with the surging success of diabetes and weight-loss medications like Ozempic poised to challenge for the top spot in 2025.

In 2024, Merck's cancer immunotherapy Keytruda solidified its position as the world's best-selling medication, generating global sales of nearly $29.5 billion. This monumental figure offers a clear answer to the question of what is the highest selling drug in the market, illustrating a significant shift in pharmaceutical leadership driven by advancements in oncology and explosive growth in metabolic therapies.

In 2024, Keytruda (pembrolizumab) dominated global sales, reaching nearly $29.5 billion, showcasing the immense value of specialized, high-cost therapies in the market. But pinpointing exactly what drug sells the most in the USA is not a simple question, as the answer varies significantly depending on whether the measure is total revenue or the sheer number of prescriptions dispensed.

In 2023, Americans spent nearly $38.6 billion on the diabetes and weight-loss drug semaglutide, making it the top-selling medication by consumer spending. The answer to what is America's best selling drug, however, depends on whether you measure by revenue, prescription volume, or a specific time frame, reflecting a dynamic and competitive market.

In 2024, Merck's immuno-oncology therapy Keytruda generated nearly $29.5 billion in sales, securing its position as the highest selling drug worldwide. The pharmaceutical landscape is highly dynamic, with new therapies and shifting demands constantly reshuffling the top ranks.

Based on 2024 sales data, Merck's Keytruda (pembrolizumab) generated nearly $29.5 billion globally, positioning it as the top-selling medication by revenue. However, this is not what is the number one prescription drug in the world when measured by the number of prescriptions filled, highlighting the complexities of defining a single market leader. The leading medication changes depending on the metric used, from generic statins to cutting-edge biologics.

With 2024 sales of nearly $29.5 billion, Merck's cancer immunotherapy drug Keytruda has solidified its market dominance [1.3.3]. So, what is the world's best selling drug and how does it compare to its closest competitors in the dynamic pharmaceutical landscape?